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Abstract
Background—Cogent evidence has shown that schizophrenia vulnerability is enhanced by 
psychosocial stress in adolescence, yet the underpinnings of this phenomenon remain elusive. One 
of the animal models that best capture the relationship between juvenile stress and schizophrenia 
is isolation rearing (IR). This manipulation, which consists in subjecting rats to social isolation 
from weaning through adulthood, results in neurobehavioral alterations akin to those observed in 
schizophrenia patients. In particular, IR-subjected rats display a marked reduction of the prepulse 
inhibition (PPI) of the startle reflex, which are posited to reflect imbalances in dopamine 
neurotransmission in the nucleus accumbens (NAcc). We recently documented that the key 
neurosteroidogenic enzyme 5α-reductase (5αR) plays an important role in the dopaminergic 
regulation of PPI; given that IR leads to a marked down-regulation of this enzyme in the NAcc, 
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the present study was designed to further elucidate the functional role of 5αR in the regulation of 
PPI of IR-subjected rats.
Methods—We studied the impact of the prototypical 5αR inhibitor finasteride (FIN) on the PPI 
deficits and NAcc steroid profile of IR-subjected male rats, in comparison with socially reared 
(SR) controls.
Results—FIN (25–100 mg/kg, i.p.) dose-dependently countered IR-induced PPI reduction, 
without affecting gating integrity in SR rats. The NAcc and striatum of IR-subjected rats displayed 
several changes in neuroactive steroid profile, including a reduction in pregnenolone in both SR 
and IR-subjected groups, as well as a decrease in allopregnanolone content in the latter group; 
both effects were significantly opposed by FIN.
Conclusions—These results show that 5αR inhibition counters the PPI deficits induced by IR, 
possibly through limbic changes in pregnenolone and/or allopregnanolone concentrations.
Keywords
5α-reductase; isolation rearing; sensorimotor gating; neurosteroids; schizophrenia; prepulse 
inhibition
1. INTRODUCTION
Ample empirical evidence has shown greater schizophrenia vulnerability in individuals 
chronically exposed to psychosocial stressors throughout early developmental stages 
(Nuechterlein et al., 1992; Norman and Malla, 1993; Walker et al., 2008). Although several 
studies have focused on the pathophysiological link between juvenile stress and psychosis 
onset (Corcoran et al., 2003), the neurobiological underpinnings of this phenomenon remain 
elusive.
One of the best tools to explore the molecular bases of the stress-diathesis model of 
schizophrenia is afforded by isolation rearing (IR), an experimental manipulation consisting 
in subjecting rodents to prolonged social deprivation from weaning through adulthood. This 
manipulation results in an array of neurobehavioral aberrations reminiscent of core 
phenotypes observed in psychotic patients (Fone and Porkess, 2008), such as the disruption 
of sensorimotor gating, measured via the prepulse inhibition (PPI) of the acoustic startle 
reflex (Geyer et al., 1993). In comparison with other behavioral alterations induced by IR, 
PPI deficits feature several operational advantages, including their correspondence with 
similar impairments in schizophrenia patients (Braff et al., 1992) and their sensitivity to 
antipsychotic agents (Bakshi et al., 1999; Binder et al., 2001). Recent findings have shown 
that the PPI deficits and other behavioral changes in IR-subjected rats are underpinned by 
alterations in dopamine (DA) (Jones et al., 1992; Hall et al., 1998; Roncada et al., 2009), one 
of the key neurotransmitters implicated in the pathophysiology of psychotic disorders. In 
particular, IR has been shown to lead to PPI disruption through DAergic imbalances in the 
nucleus accumbens (NAcc) (Powell et al., 2003), the terminal of the mesolimbic DA system. 
Indeed, ample evidence has shown that stimulation of DAergic receptors in the NAcc 
disrupts PPI in rodents (for a review, see Geyer et al., 2001).
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Several lines of evidence suggest that neuroactive steroids may contribute to the pathogenic 
role of psychosocial stress in schizophrenia (Walker et al., 2008). First, psychosocial stress 
leads to alterations in the levels of circulating steroids synthesized in the adrenal glands and 
gonads, which trigger multiple functional changes in the brain (Johnson et al., 1992; 
Huether, 1996; Kajantie and Phillips, 2006). Secondly, stress causes changes in the synthesis 
and metabolism of neurosteroids (i.e. steroids synthesized de novo in the brain; see Baulieu, 
1998), which in turn play an important role in the orchestration of the behavioral response to 
stress (Fig. 1) (Purdy et al., 1991; Barbaccia et al., 1996, 2001; Dong et al., 2001; Agis-
Balboa et al., 2007; Sanchez et al., 2008, 2009). Thirdly, neurosteroids and circulating 
neuroactive steroids have been shown to play a key role in the regulation of DA 
neurotransmission and signaling (Di Paolo, 1994; Sanchez et al., 2010). Finally, 
schizophrenia patients have been shown to feature abnormalities of neuroactive steroid 
profiles (Shirayama et al., 2002; Ritsner and Strous, 2010; Bicikova et al., 2013); in 
particular, Marx and colleagues (2006) have documented high concentrations of 
pregnenolone and dehydroepiandrosterone (DHEA) in the posterior cingulate and parietal 
cortex of schizophrenia patients. Notably, these neurosteroids may be effective adjunctive 
therapies for the management of cognitive and negative symptoms (Strous et al., 2003; Marx 
et al., 2009; Marx et al., 2011).
Building on these premises, our group has recently studied the implication of neuroactive 
steroids in the modulation of behavioral responses induced by DAergic agonists relevant to 
schizophrenia-associated phenotypes. In particular, we focused on 5α-reductase (5αR), the 
enzyme catalyzing the rate-limiting step of neurosteroidogenesis as well as the conversion of 
testosterone into its major androgenic metabolite 5α-dihydrotestosterone (DHT) (Paba et al., 
2011). Notably, we found that 5αR inhibitors oppose the PPI deficits induced by DAergic 
agonists in rodents, likely through the involvement of postsynaptic DA receptors in the 
NAcc (Bortolato et al., 2008; Paba et al., 2011; Devoto et al., 2012; Frau et al., 2013). 
Furthermore, the prototypical 5αR inhibitor finasteride (FIN), which is already approved for 
clinical use as a therapy for benign prostatic hyperplasia and androgenic alopecia, was found 
to have antipsychotic effects in a treatment-refractory case of chronic schizophrenia (Koethe 
et al., 2008). The specific molecular mechanisms by which FIN and other 5αR inhibitors 
exert anti-DAergic properties, however, remain elusive to date.
Conversely to these premises, we recently showed that IR results in a profound reduction in 
5αR expression in the NAcc (Bortolato et al., 2011). This finding, however, did not qualify 
whether this down-regulation is etiologically relevant with respect to the PPI deficits 
observed in IR-subjected rats, or rather represent a compensatory adaptive response aimed at 
balancing other molecular changes associated with those impairments. To address this 
question, in the present study we examined the functional role of 5αR in IR-induced PPI 
deficits by testing the impact of FIN on the PPI deficits and steroid profile in the NAcc of 
IR-subjected rats, as compared with socially reared (SR) counterparts. Specifically, we 
predicted that, if the IR-induced PPI deficits are caused by the reduction in 5αR expression, 
they should be exacerbated by FIN administration; vice versa, if FIN elicited antipsychotic-
like effects in IR-subjected rats, this scenario would likely signify that the down-regulation 
of 5αR in these animals does not lead to sensorimotor gating impairments.
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2. MATERIALS AND METHODS
2.1 Animals and isolation procedure
Sprague–Dawley dams (Harlan Italy, S. Pietro al Natisone, Italy) were mated with sires and 
single-housed for the whole duration of their pregnancy. Following delivery, litters were 
culled to 6 pups. At postnatal day 22, rats were weaned and males were randomly assigned 
to either IR or SR groups. To avoid litter effects, no more than two SR littermates were 
placed together in the same cage. IR-subjected rats were reared individually in plastic cages, 
while SR rats were housed four per cage. The sizes of the cages for IR and SR rats were 41 
× 26 × 20 cm and 52 × 32 × 20 cm, respectively. Animals were disturbed only for cleaning 
purposes, which consisted of changing the cage (once a week for IR-subjected rats and twice 
a week for SR controls). Both groups were housed in the same room so that IR rats 
maintained visual, auditory, and olfactory contact with the other animals. The room was 
kept under standard conditions of temperature and humidity, and food and water was 
available ad libitum. Artificial light was on from 8 PM to 8 AM. Experiments were 
conducted during the light-off phase of the day, under red light.
2.2 Drugs
Finasteride (FIN) and haloperidol (HAL) were used in this study. FIN (Polichimica, 
Bologna, Italy) was suspended in Tween 80 and diluted with 0.9% saline solution (1% 
Tween 80/saline; 1:9 vol:vol). HAL (Sigma Aldrich, Milan, Italy; Catalog N. H1512) was 
dissolved in a single drop of 1 M HCl and diluted with saline. Both drugs were administered 
intraperitoneally (i.p.) in an injection volume of 2 ml/kg, 40 min before testing. All 
experimental procedures were approved by the local ethics committee and carried out in 
strict accordance with the guidelines for experimental animals care (EEC Council 86/609; 
Italian D.L. 27/01/92, No. 116).
2.3 Startle reflex and PPI
Startle testing was performed as described in Bortolato et al. (2005). Briefly, the apparatus 
used for detection of startle reflexes (Med Associates, St Albans, VT, USA) consisted of 
four standard cages placed in sound-attenuated chambers with fan ventilation. Each cage 
consisted of a Plexiglas cylinder of 9 cm diameter, mounted on a piezoelectric 
accelerometric platform connected to an analog-digital converter. Two separate speakers 
conveyed background noise and acoustic bursts, each one properly placed so as to produce a 
variation of sound within 1 dB across the startle cage. Both speakers and startle cages were 
connected to a main PC, which detected and analyzed all chamber variables with specific 
software. Before each testing session, acoustic stimuli and mechanical responses were 
calibrated via specific devices supplied by Med Associates. After 8 weeks of IR 
manipulation (at 80 days of age), IR- and SR-subjected rats were injected with FIN (25–100 
mg/kg, i.p.), HAL (0.1 mg/kg, i.p., as positive control) or their vehicles. Each treatment 
group consisted of 8-10 rats (for a total of 108 rats). Thirty-five min after treatment, rats 
were placed in the testing cages, for a 5-min acclimatization period with a 70 dB white noise 
background that continued for the remainder of the session. Each session lasted 
approximately 25 min, and consisted of three consecutive sequences of trials (periods). 
Unlike the first and the third period, during which rats were presented with only five pulse-
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alone trials of 115 dB, the second period consisted of a pseudorandom sequence of 50 trials, 
including 12 pulse-alone trials, 30 trials of pulse preceded by 74, 78, or 82 dB pre-pulses (10 
for each level of pre-pulse loudness), and eight no stimulus trials, where only the 
background noise was delivered. Inter-trial intervals were selected randomly between 10 and 
15 s. Percent PPI was calculated using the following formula: 100−[(mean startle amplitude 
for pre-pulse pulse trials/mean startle amplitude for pulse alone trials) × 100]. As no 
significant interactions between prepulse levels and treatment were found in the statistical 
analysis, the % PPI values were collapsed to represent average PPI.
2.4. Liquid chromatography-tandem mass spectrometry analyses
A separate set of 80-day old male IR-subjected rats and SR controls were treated with either 
FIN (100 mg/kg, IP) or its vehicle (n=10–11/treatment group, for a total of 43 rats) and 
sacrificed 60 min after treatment. NAcc samples were harvested according to the indication 
of the atlas of Paxinos and Watson (1998). Given the low size of this region, analyses were 
performed on a broader area of the brain, also including the ventral and mediodorsal 
striatum, in order to achieve a critical content of neurosteroids that may be detected by LC-
MS/MS analysis. Sample extraction and purification were performed as previously 
described (Caruso et al., 2008). Briefly, samples were added with internals standards, 
homogenized in 2 ml of MeOH/acetic acid (99:1, v/v) using a tissue lyser (Qiagen, Italy). 
After an overnight extraction at 4 °C, samples were centrifuged at 12,000 rpm for 5 min and 
the pellet was extracted twice with 1 ml of MeOH/acetic acid (99:1, v/v). The organic 
phases were combined and dried with a gentle stream of nitrogen in a 40 C water bath. The 
samples were resuspended with 3 ml of MeOH/H2O (10:90, v/v) and passed through a SPE 
cartridges, previously activated with MeOH (5 ml) and MeOH:H2O 1:9 (v/v) (5 ml), the 
steroids were eluted in MeOH, concentrated and transferred in autosampler vials before the 
LC–MS/MS analysis.
Positive atmospheric pressure chemical ionization (APCI+) experiments were performed 
with a linear ion trap-mass spectrometer (LTQ, ThermoFisher Co., San Jose, CA, USA) 
using nitrogen as sheath, auxiliary and sweep gas. The instrument was equipped with a 
Surveyor liquid chromatography (LC) Pump Plus and a Surveyor Autosampler Plus 
(ThermoFisher Co., San Jose, CA, USA). The mass spectrometer was employed in MS/MS 
mode using helium as collision gas. The LC mobile phases were (A) H2O/0.1% formic acid 
and (B) methanol (MeOH)/0.1% formic acid. The gradient (flow rate 0.5 ml/min) was as 
follows: T0 70%A, T1.5 70%A, T2 55%A, T3 55%A, T35 36%A, T40 25%A, T41 1%A, T45 
1%A, T45.2 70%A, T55 70%A. The split valve was set at 0–6.99 min to waste, 6.99–43.93 
min to source and 43.93–55 to waste. The Hypersil Gold column (100 mm × 3 mm, 3 μm; 
ThermoFisher Co., San Jose, CA, USA) was maintained at 40 C. The injection volume was 
25μl and the injector needle was washed with MeOH/water 1/1 (v/v). Peaks of the LC–
MS/MS were evaluated using a Dell workstation by means of the software Excalibur® 
release 2.0 SR2 (ThermoFisher Co., San Jose, CA, USA). Quantitative analyses were 
performed on the basis of calibration curves prepared and analyzed using internal standards. 
Analyses targeted the following steroids: pregnenolone, progesterone, 5α-
dihydroprogesterone, 3α,5α-tetrahydroprogesterone (allopregnanolone), DHEA, 
testosterone, DHT, 3α,5α-androstanediol (3α-diol), and 17β-estradiol. A synoptic 
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representation of these steroids and their main metabolic pathways is provided in Fig. 1. 
Calibration curves were extracted and analyzed as described above for samples. Limits of 
detection, precision, and accuracy have been previously reported (Caruso et al., 2008).
2.5 Statistical analyses
Normality and homogeneity of variance of data distribution were verified by using the 
Kolmogorov-Smirnov and Bartlett’s tests. Statistical analyses were performed with one-way 
or two-way ANOVAs, as appropriate. Post-hoc comparisons were performed by Tukey’s 
test for factorial designs and Dunnett’s test for repeated measures. Significance threshold 
was set at 0.05.
3. RESULTS
3.1 Effects of FIN and HAL on IR-induced changes in startle amplitude and PPI
The effects of FIN on startle magnitude were analyzed by a two-way ANOVA design, with 
treatment and rearing condition as factors (Fig. 2A). While no effect of rearing conditions 
was identified [F(1,63)=2.38, ns], ANOVA detected a significant main effect for FIN 
treatment [F(3,63)=2.79, P<0.05], which was found to reflect a significant difference 
between the dose of 100 mg/kg (i.p.) and the vehicle (P<0.05, Tukey’s test). Furthermore, a 
significant interaction between rearing conditions and treatment was found [F(1,63)=3.69, 
P<0.05]. Post-hoc comparisons assessed that this effect reflected a significant difference 
between SR rats treated with the dose of 100 mg/kg and vehicle (P<0.01).
Analyses of %PPI values, performed with the same statistical design, (Fig. 2B), disclosed 
that IR-subjected rats displayed a significant reduction in this index in comparison with SR 
controls [F(1,63)=4.62, P<0.05]. While no main effects were found for the treatment 
[F(1,63)=2.20, ns], a significant rearing condition × treatment interaction was detected 
[F(3,63)=4.06, P<0.05]. Tukey’s test revealed that IR-induced PPI disruption (P<0.05 for 
IR-VEH vs SR-VEH comparison) was reversed by both 50 mg/kg (P<0.05) and 100 mg/kg 
(P<0.01) FIN doses.
It should be noted that, in a separate set of observations, none of the doses of FIN induced 
catalepsy in either IR or SR rats [F(3,63)=0.32, ns].
In a parallel set of studies, we verified the effects of HAL on IR-induced changes in startle 
amplitude and PPI (Fig. 2). HAL reduced startle amplitude [Main treatment effect: 
F(1,33)=7.18, P<0.05]. Conversely, no significant main effects for rearing condition or 
significant interactions between factors were found. PPI analyses detected significant 
differences between SR and IR-subjected rats [F(1,33)=26.69, P<0.001]. Furthermore, 
ANOVA found a main effect for treatment [F(1,33)=22.56, P<0.001], as well as a 
significant rearing condition × treatment interaction [F(1,33)=5.89, P<0.05]. Post-hoc 
analyses revealed that HAL significantly reversed the PPI deficit induced by IR condition 
(P<0.001).
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3.2 Effects of FIN on IR-induced changes in steroid profile in the NAcc
We then evaluated the effect of FIN (100 mg/kg, i.p.) on the steroid profile in the NAcc and 
striatum of IR-subjected rats and their controls. As shown in Fig. 3A, IR resulted in a 
profound reduction in the concentration of pregnenolone. [Main effect for condition: 
F(1,36)=11.55, P<0.05]. Furthermore, FIN led to a marked enhancement in the 
concentration of this steroid [Main effect for treatment: F(1,36)=25.10; P<0.0001]. No 
interactions between condition and treatment were found [F(1,36)=7.63, ns]. Analyses of 
progesterone levels (Fig. 3B) found that this neuroactive steroid was not influenced by IR 
[[Main effect for condition: F(1,36)=1.42, ns], FIN treatment [Main effect for treatment: 
F(1,36)=0.45, ns] or their interaction [F(1,36)=1.00, ns]. In line with these results, the 
analysis of progesterone/pregnenolone ratio disclosed a significant enhancement in IR-
subjected rats (Main effect: IR vs SR: P<0.05) and a dramatic reduction caused by FIN 
treatment (Main effect: FIN vs vehicle: P<0.0001) (Fig. 3H). As shown in Fig. 3C, we found 
that 5α-dihydroprogesterone levels were significantly reduced by IR [Main effect for 
condition: F(1,38)=4.25, P<0.05], but not by FIN [Main effect for treatment: F(1,38)=0.98, 
ns] or by condition × treatment interactions [F(1,38)=1.49, ns]. In addition, the 5α-
dihydroprogesterone / progesterone ratio (Fig. 3I) was found to be reduced by IR (Main 
effect for rearing condition: F(1,32)=5.07, P<0.05). However, this parameter was not 
affected by FIN [Main effect for treatment: F(1,32)=0.32, ns; rearing × treatment 
interaction: F(1,32)=0.72, ns]. The analyses of allopregnanolone levels revealed no main 
effects for either rearing condition [F(1,36)=0.11, ns] or treatment [F(1,36)=0.34, ns]; 
however, a significant interaction of rearing condition and treatment was found 
[F(1,36)=7.86, P<0.01]. Post-hoc analyses revealed that, while vehicle-treated IR-subjected 
rats exhibited a significant reduction in allopregnanolone levels in comparison with their SR 
counterparts (P<0.05), FIN treatment induced a paradoxical enhancement in 
allopregnanolone levels in IR rats (P<0.05) (Fig. 3D). These results were paralleled by the 
changes in allopregnanolone/5α-dihydroprogesterone ratio, which revealed a positive 
rearing × treatment interaction [F(1,36)=9.14; P<0.01]. Indeed, SR vehicle-treated rats were 
found to display higher ratios than either IR vehicle-treated (P<0.05) or SR FIN-treated 
(P<0.01) rats. Furthermore, in IR rats FIN enhanced this ratio (P<0.01) in comparison with 
vehicle-treated counterparts (Fig. 3J).
While DHEA levels were not affected by IR [Main effect for condition: F(1,39)=0.77, 
P<0.05], we found a statistical trend for a reduction induced by FIN [Main effect for 
treatment: F(1,39)=3.43, P=0.07], but no condition × treatment interactions (Fig. 3E). The 
DHEA/Pregnenolone ratio was found to be increased by IR and reduced by FIN (Main 
effects: Ps<0.01) (Fig. 3K). While IR failed to affect testosterone levels (Fig. 3F), it caused a 
reduction in estradiol levels [Main effect for condition: F(1,38)=5.51, P<0.05] (Fig. 3G); 
conversely, FIN failed to affect the levels of either steroid (Figs. 3F–G). No significant 
differences were found in the analysis of the estradiol/testosterone ratio (Fig. 3L). Levels of 
DHT and 3α-diol could not be compared reliably, as their concentrations remained under 
detection limits in more than 70% of samples.
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The main finding of the present study is that the potent 5αR inhibitor FIN dose-dependently 
countered the deficits in PPI caused by IR, a well-characterized neurodevelopmental model 
of juvenile psychosocial stress leading to schizophrenia-related alterations. Similarly to 
previous experiments (Bortolato et al., 2008), the effects of FIN were generally similar to 
those of the benchmark antipsychotic HAL; in spite of this analogy, the 5αR blocker failed 
to induce catalepsy or other overt extrapyramidal manifestations. This result confirms and 
extends our previous observations on the ameliorative effects of FIN and other 5αR 
inhibitors on psychosis-related alterations elicited by direct and indirect DAergic agonists in 
rodents (Bortolato et al., 2008; Devoto et al., 2012; Frau et al., 2013). Furthermore, these 
data support preliminary clinical evidence on the possible therapeutic potential of FIN in 
schizophrenia (Koethe et al., 2008), as well as other disorders featuring DAergic alterations, 
including Tourette syndrome (Bortolato et al., 2007; Muroni et al., 2011) and impulsive 
behaviors induced by DAergic agonists in susceptible patients (Bortolato et al., 2012).
In agreement with our previous findings (Bortolato et al., 2008; Devoto et al., 2012), startle 
reflex was significantly reduced by FIN in SR animals. This phenomenon, however, was not 
observed in IR-exposed animals, suggesting that IR may reduce sensitivity to the effects of 
5αR inhibitors with respect to startle reactivity. Notably, the lack of a selective effects of 
FIN on startle amplitude in IR animals also rules out possible confounds in PPI analysis due 
to alterations in this parameter (Swerdlow et al., 2000).
We previously showed that the effects of FIN on the regulation of PPI are likely supported 
by changes in the signaling of the postsynaptic DA receptors in the NAcc (Devoto et al, 
2009). Furthermore, several studies have shown that the gating deficits induced by IR are 
primarily mediated by this region (Powell et al., 2003; Leng et al., 2004). Our results 
showed that IR leads to significant reductions in pregnenolone, 5α-dihydroprogesterone, 
allopregnanolone and estradiol in the NAcc. These data are in substantial agreement with 
previous findings from our group and others, indicating that IR leads to an overall reduction 
in steroid levels in the cortex (Serra et al., 2000; Bortolato et al., 2011). We also documented 
no significant changes in progesterone, DHEA and testosterone levels, suggesting that the 
generalized reduction in neurosteroid biosynthetic pathways may be partially offset by the 
down-regulation of catabolic enzymes and/or the activation of alternative anabolic 
processes. The significant changes in steroid ratios are in keeping with the previously 
documented down-regulation of 5αR in IR-subjected rats (as indicated by the reduction in 
5α-dihydroprogesterone / progesterone ratio); furthermore, our data suggest that this 
manipulation may lead to functional alterations of other neurosteroidogenic enzymes, such 
as a potential enhancement of the activity of 3β-hydroxysteroid dehydrogenase (3β-HSD), 
which catalyze the conversion of pregnenolone into progesterone (see Fig. 4).
Our results indicated that IR led to a significant reduction in 17β-estradiol, but not 
testosterone, in IR-subjected rats. Both steroids have been shown to be potentially relevant 
in the control of negative symptoms in schizophrenia (Shirayama et al., 2002; Rao and 
Kolsch, 2003; Akhondzadeh et al., 2006). Due to the relatively small size of our biological 
samples, we were unable to obtain a reliable measurement of 5α-reduced androgens, such as 
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DHT and 3α-diol, or testosterone precursors, such as androstenedione; thus, we cannot fully 
evaluate whether the lack of variations in testosterone levels were reflective of changes in its 
synthesis or 5αR-mediated metabolism. Nevertheless, it is worth mentioning that, while we 
did not find any significant changes in aromatase activity (as estimated by the testosterone / 
estradiol ratio), IR-exposed rats exhibited a significant reduction in estradiol levels, which 
may have been caused by an enhancement in the metabolic pathways of this steroid, namely 
its conversion to estrone by 17β-hydroxysteroid dehydrogenase (Labrie et al., 1997), or its 
16α-hydroxylation to estriol, which is primarily mediated by several cytochromes P450 
(Badawi et al, 2001). Further studies are warranted to assess the effects of sex steroids on 
the behavioral and neurochemical sequelae of IR, and to study the implications of this 
manipulation on testosterone and estradiol-metabolic enzymes.
The behavioral effects of FIN were paralleled by a marked increase in the concentrations of 
pregnenolone and a statistical trend for an enhancement of DHEA levels in the NAcc and 
striatum. The increased content of these 3β-hydroxy-Δ5-steroids may signify their 
accumulation in response to the inhibition of 5αR, given that they are the precursors of the 
two main 5αR substrates, i.e. progesterone and testosterone. The possibility that the 
antipsychotic-like actions of FIN may be contributed by the enhancement of pregnenolone 
(and, possibly, DHEA) levels is in keeping with emerging evidence supporting the 
therapeutic potential of these neurosteroids for cognitive and negative symptoms in 
schizophrenia (Strous et al., 2003; Marx et al., 2009; Marx et al., 2011; Ritsner et al., 2014). 
Furthermore, pregnenolone was recently shown to rescue the spontaneous PPI deficits in DA 
transporter knockout mice, which are also reflective of DA receptor hyperactivation in the 
NAcc (Wong et al., 2012). As mentioned in the introduction, alterations in levels of brain-
regional pregnenolone and DHEA have been documented in schizophrenia (Marx et al., 
2006). Furthermore, changes in plasma concentrations of DHEA and pregnenolone (as well 
as their sulfoconjugated derivatives) have also been documented in schizophrenia patients 
(Harris et al., 2001; Strous et al, 2004; di Michele et al, 2005; Silver et al., 2005; Gallagher 
et al, 2007; Ritsner et al., 2006, 2007; Ritsner and Strous, 2010; Bicikova et al., 2013). In 
particular, changes in the concentrations of circulating neuroactive steroids and their ratios 
may be related to specific symptomatic aspects of schizophrenia, such as cognitive 
symptoms, anxiety and stress responsiveness (Ritsner et al., 2007; Ritsner and Strous, 2010). 
Although the biological actions of pregnenolone and DHEA are not completely understood, 
they act as potent agonists of σ1 receptors (Maurice et al., 2001), which have been shown to 
be essential for the modulation of DA D1 receptor signaling (Navarro et al., 2010). Notably, 
we recently showed that the PPI-ameliorating properties of FIN are due to the suppression of 
D1 receptor signaling (Frau et al., 2013). In addition, pregnenolone and DHEA have been 
shown to exert neuroprotective properties against apoptosis and oxidative damage (for a 
review, see Ritsner, 2010), which may play an important role in shaping the 
pathophysiology of schizophrenia (Yao et al., 2001; Jarskog, 2006). Future studies will be 
needed to elucidate whether the effects of FIN in IR-subjected rats are mediated by 
pregnenolone and DHEA, and substantiate the role of σ1 receptors on the regulation of PPI 
and other schizophrenia-related endophenotypes.
We found that, while FIN reduced allopregnanolone levels and allopregnanolone / 5α-
dihydroprogesterone ratio in SR rats, this drug had surprisingly opposite effects in IR-
Frau et al. Page 9













subjected rats. This paradoxical phenomenon may have been caused by functional changes 
in 3α-hydroxysteroid oxidoreductase (3α-HSOR), the reversible enzyme involved in the 
inter-conversion of allopregnanolone and 5α-dihydroprogesterone. Indeed, this enzyme has 
been shown to serve both the synthesis and degradation of allopregnanolone, depending on 
the prevalence of its cytosolic or membrane-bound isoform (Mellon and Vaudry, 2001). 
Depending on the changes induced by IR on the expression and activity of this enzyme, the 
acute 5αR inhibition may have altered the inter-regulatory cross-talk between these two 
enzymes, leading to a reduction of the conversion of allopregnanolone into 5α-
dihydroprogesterone.
Alternatively, the increase in allopregnanolone may reflect an altered mechanism of action 
of FIN, possibly due to putative alterations in 5αR structure and intracellular localization in 
IR-subjected rats. In order to inhibit 5αR, FIN needs to be accepted as a substrate of this 
enzyme and reduced to dihydroFIN; in turn, this metabolite forms an adduct with NADP, 
which is then covalently bound to the enzyme (Bull et al., 1996). Thus, the down-regulation 
of 5αR may limit its transformation into dihydroFIN and unmask other secondary 
mechanisms of this drug, such as the inhibition of 5β-reductase (Drury et al., 2009), which 
may paradoxically enhance the synthesis of allopregnanolone and other 5α-reduced 
neurosteroids.
The enhancement in allopregnanolone in IR rats may play a key contributory role in the 
effects of FIN. Allopregnanolone is known to activate GABA-A receptors, whose action 
may indeed interact with potential changes in DA receptor signaling in DAergic regions. 
Interestingly, allopregnanolone has been shown to counter the enhancement of aggression 
and fear-related memory in isolated mice (Pinna et al., 2008). Future studies will be needed 
to test the potential role of allopregnanolone in the modulation of PPI by FIN in IR-
subjected rats.
Although our results may provide critical element of insight into the role of 5αR in the 
regulation of PPI, several limitations need to be acknowledged. Our neuroactive steroid 
analyses could not be limited to NAcc, in view of the small size of this region, and 
incorporated also the striatum; however, it is possible that the two regions, albeit organized 
similarly, may different significantly with respect to steroid profiles. In addition, our studies 
failed to test whether the changes in neuroactive steroids in the NAcc may be directly 
conducive to changes in PPI. Future studies with systemic and intra-accumbal infusion of 
pregnenolone and allopregnanolone will be needed to confirm the potential involvement of 
these steroids in the therapeutic actions of FIN.
Another important limitation of our study lies in the fact that the alterations in steroid profile 
in the NAcc were tested in a separate group of rats that did not undergo PPI testing. Given 
that startle testing is stressful in rats (Engelmann et al., 1996), we cannot exclude that the 
effects of FIN in PPI regulation may target other unknown changes in neurosteroids 
specifically induced by behavioral testing. This possibility will need to be accurately 
evaluated in future studies.
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Our study did not include any analysis on the steroid profiles in either plasma or other 
potentially relevant regions in the DAergic system, including the midbrain. Although 
previous studies have documented that the PPI deficits induced by IR are primarily 
dependent on the NAcc, functional alterations in the ventral tegmental areas may lead to 
changes in DAergic neurotransmission. This interesting possibility awaits further 
experimental confirmation in future investigations.
Finally, our findings did not qualify the 5αR isoform implicated in the antipsychotic-like 
effects of FIN in IR-subjected rats. The two major types of 5αR, 1 and 2, are both expressed 
in the NAcc and down-regulated by IR (Bortolato et al., 2011; Castelli et al., 2013). In 
particular, the involvement of 5αR2 in the observed effects of FIN may be particularly 
meaningful from a translational perspective, given that FIN has a higher affinity for this 
isoenzyme in humans (Paba et al., 2011). Furthermore, given the importance of 5αR2 in the 
synthesis of androgens, its implication in the anti-DAergic mechanisms of FIN may account 
for recent findings from our group on PPI-ameliorating properties of abiraterone, the main 
androgen-synthetic enzyme, in rats (Frau et al., 2014). The involvement of androgens in the 
effects of FIN may also provide a mechanistic frame to account for the well-documented sex 
differences in schizophrenia and their relation to DAergic signaling (Godar and Bortolato, 
2014).
Irrespective of these limitations, our findings have confirmed FIN’s antipsychotic-like 
properties, by documenting its ability to correct the gating alterations associated with IR, a 
neurodevelopmental model of schizophrenia with high face, construct and predictive 
validity. The actions of FIN are accompanied by changes in neuroactive steroid levels, such 
as an increase in pregnenolone and allopregnanolone, which countered the effects of IR. 
These data further confirm previous evidence pointing to 5αR as a promising target for the 
development of novel treatments for schizophrenia and other neuropsychiatric disorders 
featuring stress-related gating impairments, such as Tourette syndrome and obsessive-
compulsive disorder.
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Schematization of the major biosynthetic pathways of neurosteroids. Cholesterol is 
converted to pregnenolone by cytochrome P450 side-chain cleavage (scc). Pregnenolone is 
then processed either to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD) or to 
dehydroepiandrosterone (DHEA) by 17-hydroxylase/17,20 lyase (CYP17A1). The 
conversion of progesterone to dihydroprogesterone is catalyzed by 5α-reductase (5αR). 
Dihydroprogesterone can be metabolized by the reversible enzyme 3α-hydroxysteroid 
oxidoreductase (3α-HSOR) and 3β-hydroxysteroid oxidoreductase (3β-HSOR) for the 
synthesis of allopregnanolone and isopregnanolone, respectively. DHEA is metabolized to 
androstenedione, which is then converted to testosterone by 17β -hydroxysteroid 
dehydrogenase (17β-HSD). Testosterone is the converted into estradiol by aromatase 
(CYP19A1); alternatively, the combined metabolic reactions of 5αR, 3α- and 3β-HSOR 
metabolize testosterone into its androgenic derivatives dihydrotestosterone (DHT), 3α- and 
3β-androstanediol, respectively.
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Effects of finasteride (F) and haloperidol (HAL) on startle magnitude (A) and %PPI (B) in 
isolation-reared (IR) and socially-reared (SR) rats. Values represent mean ± SEM for each 
experimental group. Treatments are indicated below the horizontal axis. All doses are given 
in mg/kg (IP). VEH, vehicle of finasteride. SAL, saline (vehicle of HAL). * P<0.05, ** 
P<0.01 in comparison to SR-VEH group; # P<0.05, ## P<0.01, in comparison to IR-VEH 
group. § P<0.05 in comparison to SR-SAL group; ◊◊◊ P<0.001 in comparison to IR-SAL 
group. For further details, see results section.
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Effects of finasteride (FIN; 100 mg/kg, i.p.) and its vehicle (VEH) on the levels of 
neuroactive steroids in the Nucleus Accumbens and striatum of isolation-reared (IR) and 
socially-reared (SR) rats. Treatments are indicated below the horizontal axis. $$, P<0.01; $$
$, P<0.001 in comparison with vehicle-treated rats (main effect for treatment); ^, P<0.05; ^^, 
P<0.01 in comparison with SR rats (main effect for rearing condition); * P<0.05; **, P<0.01 
in comparison to VEH-SR group (rearing condition × treatment interaction); # P<0.05, ## 
P<0.01 in comparison to VEH-IR group (rearing condition × treatment interaction). VEH, 
vehicle; FIN, finasteride; PREG, pregnenolone; PROG, Progesterone; DHP, 5α-
dihydroprogesterone; AP, allopregnanolone; DHEA, dehydroepiandrosterone; TEST, 
Testosterone; ESTR, 17β-estradiol. For further details, see results section.
Frau et al. Page 18














Synoptic schematization of the observed effects of isolation rearing (IR) and finasteride 
(FIN) on neurosteroid levels in the nucleus accumbens (NAcc). Black and white arrows 
represent increased and decreased enzyme activities, respectively. CYP17A1, 17-
hydroxylase/17,20 lyase; 3β-HSD, 3β-hydroxysteroid dehydrogenase; 5αR, 5α-reductase; 
3α-HSOR, 3α-hydroxysteroid oxidoreductase; DHEA, dehydroepiandrosterone. For further 
details, see text.
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